(2-Guanidinoethylmercapto)succinic acid | 77482-44-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2-Guanidinoethylmercapto)succinic acid
• 英文别名: (2S)-2-[2-(diaminomethylideneamino)ethylsulfanyl]butanedioic acid
• CAS: 77482-44-1
• 化学式: C₇H₁₃N₃O₄S
• 分子量: 235.26
• InChiKey: VKVCLXDFOQQABP-BYPYZUCNSA-N

物化性质

• 熔点：
  ~180 °C (dec.)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  164
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 安全说明：
  S22,S24/25
• 海关编码：
  2930909090

文献信息

• Pharmaceuticals
  申请人：——

  公开号：US20020147229A1

  公开（公告）日：2002-10-10

  The present invention provides compounds of formula (I) 1 as well as the use of such compounds in pharmaceutical compositions and methods of treatment. The compounds described herein represent a class of TAFIla inhibitors suitable for use in treating conditions such as thrombosis, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

  本发明提供了式(I)1的化合物，以及这些化合物在制药组合物和治疗方法中的应用。本文描述的化合物代表了一类适用于治疗血栓形成、动脉粥样硬化、粘连、皮肤瘢痕、癌症、纤维化疾病、炎症性疾病以及那些受益于维持或增强体内激肽酶激活因子Ⅰ（TAFIla）抑制剂的疾病的化合物。
• 3-(Imidazolyl)-2-aminopropanoic acids
  申请人：Pfizer Inc.

  公开号：US20030191107A1

  公开（公告）日：2003-10-09

  Compounds according to formula (I) wherein n is 1-4, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  根据公式(I)，其中n为1-4，R1是可选取代的C1-6烷基、C2-6烯基或C2-6炔基、杂环、芳香杂环、芳基或氢，而R2、R3、R4、R5、R6、R7和R8各自独立选择自氢和可选取代的C1-6烷基的化合物是新颖的。它们在治疗血栓症和与纤维蛋白沉积相关的其他病理情况中非常有用。
• 3-(Imidazolyl)-2-alkoxypropanoic acids
  申请人：Pfizer Inc.

  公开号：US20030199522A1

  公开（公告）日：2003-10-23

  Compounds according to formula (I) wherein n is 0-3, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R 5 and R 8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  根据公式（I）中的化合物，其中n为0-3，R1为可选择的取代C1-6烷基，C2-6烯基或C2-6炔基，杂环，芳香杂环，芳基或氢，而R2、R3、R4、R5、R6、R7、R8和R9分别独立选择自氢和可选择取代的C1-6烷基，或R5和R8为烷基链，是新颖的。它们在治疗与纤维蛋白沉积相关的血栓性疾病和其他病理条件中具有用途。
• [EN] SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS<br/>[FR] IMIDAZOLES SUBSTITUES UTILISES COMME INHIBITEURS TAFIA
  申请人：PFIZER LTD

  公开号：WO2002014285A1

  公开（公告）日：2002-02-21

  The present invention provides compounds of formula (I). These compounds are a class of TAFIa inhibitors, atherosclerosis, adhesions, dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions which benefit from maintaining or enhancing bradykinin levels in the body.

  本发明提供了化合物(I)的类别，这些化合物是一种TAFIa抑制剂，可用于治疗动脉粥样硬化、粘连、皮肤瘢痕、癌症、纤维化疾病、炎症性疾病以及那些需要维持或增强体内缓激肽水平的疾病。
• 3-(imidazolyl)-2-alkoxypropanoic acids
  申请人：Pfizer Inc.

  公开号：US20040254164A1

  公开（公告）日：2004-12-16

  Compounds according to formula (I) wherein n is 0-3, R′ is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R 5 and R 8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  化学式为（I）的化合物中，n为0-3，R′为可选取代的C1-6烷基，C2-6烯基或C2-6炔基，杂环，芳香杂环，芳基或氢，而R2，R3，R4，R5，R6，R7，R8和R9各自独立地选择氢和可选取代的C1-6烷基，或者R5和R8是一个烷基链，这些化合物是新颖的。它们在治疗与纤维蛋白沉积相关的血栓性疾病和其他病理情况中有用。